Haw Par (SGX:H02) Earnings Fell While Dividend Held, Is The Stock Still Cheap?

What Haw Par’s latest earnings and dividend mean for investors

Haw Par (SGX:H02) has just reported half year 2026 results that show weaker sales and net income, while keeping its first and interim cash dividend unchanged at $0.20 per share and confirming key payout dates.

See our latest analysis for Haw Par.

Haw Par’s share price is now at SGD14.97, and the recent earnings miss has coincided with a 30 day share price return that is down 7.42%. However, the 3 year total shareholder return of 80.40% still reflects a much stronger longer term outcome.

If this earnings update has you thinking about where else opportunities might be building, it could be a good time to scan the market for resilient businesses through the 114 top founder-led companies

Bulls may view Haw Par’s recent share price decline and consistent dividend as a potential entry point, while bears may emphasise the softer earnings. The key question is which case is better supported by current valuation metrics.

Preferred P/E of 14.5x for Haw Par, is it justified?

Haw Par is trading on a P/E of 14.5x, which screens as relatively low compared to peers at the current share price of SGD14.97.

The P/E multiple compares what you pay today for each dollar of current earnings. For a diversified healthcare and investment group like Haw Par, it is a quick way to see how the market is pricing its profit profile.

Here, the stock trades below both the peer average P/E of 16.6x and the broader Asian pharmaceuticals P/E of 22.5x. It also sits close to an estimated fair P/E of 14.9x that our fair ratio work suggests the market could gravitate toward over time.

That combination points to a company that is trading at what looks like good relative value when set against its industry and a data driven fair ratio framework.

Explore the SWS fair ratio for Haw Par

Result: Price-to-earnings of 14.5x (UNDERVALUED)

However, Haw Par still faces risks if healthcare demand softens, or if returns from its quoted securities and investment properties come under pressure.

Find out about the key risks to this Haw Par narrative.

Another view on Haw Par’s valuation

While Haw Par screens as good value on a P/E of 14.5x, the SWS DCF model paints a different picture. At a share price of SGD14.97, the stock is trading above an estimated future cash flow value of SGD5.80, which points to a potential overvaluation on this method. So which signal should carry more weight for you right now?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Haw Par for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 271 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Haw Par showing a mix of weaker earnings and ongoing dividends, the overall picture is not one sided. Act while the numbers are fresh and weigh the trade off between potential upside and the risks that could hold the stock back through 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Haw Par?

If Haw Par’s latest update has sharpened your focus, now is a smart moment to widen your watchlist and compare it with other focused opportunities on Simply Wall St.

• Target potential bargains that pair quality with attractive pricing by scanning the market using the 271 high quality undervalued stocks.
• Strengthen your income stream by reviewing reliable payers through the 424 dividend fortresses.
• Reduce portfolio shocks by concentrating on companies assessed to be more resilient via the 294 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com